Care continues to improve; however, drug-resistant pathogens and a lack of new agents to treat these infections remain a constant challenge.
David Cluck, PharmD, BCPS, AAHIVP
Advertisement
Articles by David Cluck, PharmD, BCPS, AAHIVP
Should clinicians be extra vigilant when deciding who receives antiviral therapy, or are the adverse effects few and infrequent?
Advertisement
Latest Updated Articles
- Risks Associated With Direct-Acting Antivirals—Smoke or Fire?
Published: May 9th 2017 | Updated:
- Guidelines to Caring for Patients With Sepsis: Promise or Progress?
Published: August 8th 2017 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
CDC's Latest Hepatitis B Vaccine Guidance Serves as Example for Future Federal Vaccine Policy
2
Growing International Evidence Suggests Emerging Metallo-β-Lactamase Therapy Could Benefit US Clinicians
3
Addressing the Three Pillars of PPE in Caring for Patients with High-Consequence Infectious Disease
4
Vigilance, Training, and Funding are Key for Outbreak and Pandemic Biopreparedness
5